Avista Therapeutics has partnered with Roche to develop adeno-associated virus (AAV) gene therapy vectors for eye diseases. The collaboration is primarily based on Avista’s single-cell AAV engineering platform, scAAVengr, to further develop intravitreal AAV capsids which compliment a capsid profile defined by Roche. The deal, which is worth up to US$1 B, marks Avista’s first partnership with Roche in the ophthalmology segment as the companies aim to find an effective solution for visually impaired patients.